Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Muscle-Invasive Bladder Cancer
NCT00380029Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- May 2006
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in muscle-invasive bladder cancer (MIBC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: EGFR Activation Signal (AKT2) Expression to Predict Sensitivity to Erlotinib. Started May 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT00380029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00380029.